Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions by unknown
Brief Definitive Report 
Suboptimal Activation of Melanoma Infiltrating 
Lymphocytes  (TIL)  due to Low Avidity of 
TCR/MHC-Tumor  Peptide Interactions 
By Nadine Gervois, Yannick Guilloux,  Elisabeth Diez, 
and Francine  Jotereau 
From the Institut National  de la Sant~ et de la Recherche M~dicale and Facult~ des Sciences de Nantes, 
44035 Nantes  cedex 0I, France 
SunuTlal~ 
Coculture of melanoma cells and T  cell clones derived from tumor-infiltrating lymphocytes 
(TIL) generally results in lysis of the antigen-bearing tumor cells but to inefficient proliferation 
and IL-2 secretion by responder T cells. This suboptimal activation is classically explained by an 
inability of tumor cells to provide costimulatory signals. Here we analyzed the responses to syn- 
thetic peptides of HLA-A2.1-restricted CTL clones specific for melanoma antigens MART-1 
and NA17-A. We showed that peptide concentrations ranging from 1 pM to 10 nM efficiently 
sensitized the peptide transporter-deficient T2 cells  to lysis.  T2  cells  pulsed with melanoma 
peptides also induced TIL proliferation and detectable secretion of IL-2, IFN-~/and GM-CSF, 
but  only for peptide concentrations 10- to  10,000-fold higher than those required for lysis. 
Hence this suggests that partial triggering of TIL clones by melanoma cells could be due to ex- 
pression of appropriate MHC-peptide complexes at subthreshold levels. In support of this, we 
showed that melanoma cells, unable to trigger IL-2 secretion, developed this ability when in- 
cubated with the appropriate peptide. These results indicate that the level of antigens expressed 
on melanoma tumors critically affects TIL activation status  and thus, the efficiency of specific 
immune reactions mediated by these cells. 
A 
number of melanoma-derived peptides, recognized in 
vitro by autologous T  lymphocytes, have been identi- 
fied  recently (1).  Little is known,  however, about the ca- 
pacity of these epitopes to trigger efficient T  cell activation 
and immune reactions in vivo. It is widely assumed that T 
cell activation  requires  two  signals.  Signal  one  originates 
from the ligation of the T  cell receptor and its coreceptors. 
Signal two, which is not antigen specific, is generated by 
either soluble factors such as IL-2 or by interactions with 
surface molecules expressed by antigen presenting cells (see 
reference 2 for a review). The best characterized costimula- 
tory signal for T lymphocytes is mediated by CD28-B7 in- 
teractions  (see reference 3 for a review). Classically,  T  cells 
that bind antigen but do not receive a costimulatory signal 
become  anergic.  Since  melanoma  ceils,  as  most  non- 
hemopoietic tumors,  do not  express costimulatory mole- 
cule, such as B7-1 or B7-2, it has been speculated that they 
could anergize tumor-specific TIL  1 by delivering an anti- 
genic signal only (3). To address  this issue we have derived 
a  number of melanoma  TIL clones  and  extensively ana- 
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lyzed their reactivity against tumor cells  in vitro. We re- 
ported recently that most melanoma infiltrating T cell clones 
(TIL) stimulated by melanoma cells efficiently killed these 
cells and secreted TNF, but few of them produced detect- 
able  levels  of IL-2  and  IFN-'y  (4).  However,  suggesting 
that  defective costimulation was  not  the  main  reason for 
partial TIL triggering, we had shown that melanoma cells 
induced to express B7-1 by gene transfection, did not trig- 
ger either a full TIL activation (5). This did not appear to 
be due to a functional defect of TIL clones as they secreted 
large  amounts  of IL-2  following  CD3  cross-linking  (4). 
Furthermore, melanoma lines unable to stimulate IL-2 se- 
cretion by TIL efficiently triggered this response once in- 
duced  to  express high  levels of LFA-3,  after transfection 
(reference 4  and  unpublished  data).  Together these  data 
suggested that defective TIL activation by melanoma lines 
was due to delivery of a suboptimal antigenic signal.  This 
led us to investigate whether the nature, agonist or partial 
agonist, or the density of melanoma peptides expressed on 
tumor cells could be responsible for partial TIL activation. 
To  address  this,  we  analyzed  the  ability  of HLA-A2.1- 
restricted  epitopes  from  melanoma  antigens,  MA1LT-1/ 
Melan-A  (6-8)  and  NA17-A  (9)  to  induce  secretion  of 
IL-2, IFN-y, GM-CSF,  and TNF by specific TIL clones. 
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creasing  amounts  of their  specific  peptides,  presented  by 
the  (TAP-) peptide transporter-deficient T2 cell line or by 
melanoma cells.  We show that human melanoma peptides 
recognized by TIL are  full  agonists  and  that  hyporespon- 
siveness  of MART-l-  or NA17-A-specific TIL clones  to 
melanoma cells in vitro is not due to a defective TIL func- 
tion  but  to  expression  of  suboptimal  levels  of  specific 
MHC-peptide complexes on melanoma cells in vitro. 1kel- 
evance of these data to melanoma vaccine development are 
discussed. 
Materials  and Methods 
Cell Lines.  Tumor cell line M17 was derived from the meta- 
static  melanoma  of patient  M17.  The  human  mutant  cell  line 
CEMx721.174.T2 (T2) (10) used as presenting cells and the mouse 
fibrosarcoma  WEHI  164  done  13  cells, used  for TNF  assays, 
were obtained from Dr. P. Coulie (Ludwig Institute  for Cancer 
g.esearch,  Brnssels, Belgium).  All these  cell lines are  cultured in 
RPMI containing 10% FCS. 
Generation of Melanoma-specific TIL Clones.  Production, charac- 
terization and culture  of human TIL derived  clones  have been 
described  in  detail  previously  (11). Specificity  and  restriction 
were investigated  using various functional assays including prolif- 
eration, cytolysis, and lymphokine secretion (4, 5). 
Synthetic Peptides.  Peptides  were  synthetized on  solid  phase 
using F-moc for transient  NH2-terminal protection as described 
(12),  and were  characterized by mass spectrometry.  Purity was 
controlled  by  analytic  HPLC.  Lyophilized peptides  were  dis- 
solved at 10 ms/m1 in DMSO and stored at -80~ 
slChromium Micro~totoxicity Assay.  1,000  SlCr-labeled  target 
cells (T2 or melanoma cells) were incubated for 30 min at room 
temperature with various concentrations of peptide before addi- 
tion of 10,000 lymphocytes. After 4 h of incubation at 37~  100 
~1  of supernatant  were  harvested  and  radioactivity was  deter- 
mined in a gamma counter. 
Cytokine Production Assays.  At least 10 d after the last stimula- 
tion,  T  cells were washed thoroughly. 10  q T  lymphocytes were 
mixed with 3  ￿  104 target cells pulsed  with different  concentra- 
tions ofpeptide, in 200 ~1 of culture medium. Control assays were 
done in which the lymphocytes were incubated with peptides  in 
the absence of target cells. Supematants were harvested 24 h later. 
The IL-2 dosage was done using the CTLL-2 cell line prolifera- 
tion assay, compared to a standard  curve with rIL-2 (Cetus).  No 
IL-2 production was detected in the absence  of target cells (data 
not  shown),  showing  that  T  lymphocytes  did  not  efficiently 
present these peptides.  TNF determinations were done by a bio- 
logic assay using cytotoxicity on the highly sensitive WEHI 164 
clone 13 cells, compared to a standard curve with rTNF43 (Gen- 
zyme Corp.,  Cambridge, MA)  (13).  IFN-~ and GM-CSF con- 
centrations  were assessed by immunoenzymatic assays (Medgenix 
Diagnostics  and  Immunotech International):  limits  of detection 
were 0.03  IU/ml and 1.5 pg/ml, respectively.  The relative  pep- 
tide index is calculated by dividing peptide concentrations induc- 
ing half maximum responses  (lysis, TNF,  IFN-"/ and GM-CSF 
secretion)  by the  concentration  inducing,  in  the  same  experi- 
ment, half maximum IL-2 secretion. 
Proliferation Assays.  Microcultures were set up in triplicate  in 
96-well culture plates. Briefly,  104 T  cells were cultured for 3 d 
with 3 X  104 irradiated  peptide-pulsed melanoma cells in 200 ~1 
of medium without IL-2. Proliferation was determined by adding 
1 p~Ci of3H thymidine (3HT) to each well  for the last 18 h of 
culture.  3HT  uptake  was  measured  in  a  liquid  scintillation 
counter. 
Results and Discussion 
Lytic and Cyt&ine Responses of TIL Clones Are Triggered by 
Peptide-loaded  T2 Cells.  CTL clones used here  have been 
described  elsewhere  (11).  They  were  derived  from  two 
melanoma tumors M17 and M77. They all recognized their 
epitope  in  the  HLA-A2A  context.  Clone  M17.2  was 
shown to recognize a peptide  shared by a high proportion 
of melanoma  lines  (14).  Recently  the  antigen  recognized 
by this CTL clone was identified and called NA17-A. Ex- 
pression  of this  antigen was shown  to be  restricted  essen- 
tially to melanoma tumors (9).  Only two overlapping pep- 
tidic  sequences  deduced  from  NA17-A  gene  sequence, 
Acl-9 and  1-10 were recognized, at about the same levels, 
by clone M17.2 (9). MART-l-specific clones, M77.80, 84, 
86 and 25, were shown to be distinct by CDR3 sequencing 
(Pannetier,  C., unpublished).  Analysis of their reactivity to 
MAtLT-1  sequences,  Ac27-35,  26-35,  27-36,  and  32-40 
previously reported to be the HLA-A2.1 restricted epitopes 
recognized by TIL (8)  revealed  that  all  clones recognized 
MAR.T-1 Ac26-35 and/or 27-35. Whereas clone M77-80 
responded  at  about  the  same  level  to  both  epitopes,  the 
other three clones (84, 86, and 25) responded much better 
to  the  decamer  Ac26-35  (our  unpublished  data).  There- 
fore, one or both of these peptides probably corresponded 
to the  naturally presented  epitope  on HLA-A2.1-express- 
ins melanoma cells.  The T2 cell line was used to titrate the 
responses  of TIL clones  to  MART-1  and  NA17-A pep- 
tides.  As shown in Fig.  1, peptide  concentrations between 
0.6 pM and 10 nM efficiently sensitized T2 cells  to lysis by 
TIL clones. These concentrations are close to or lower than 
commonly described  stimulatory  concentrations  of T  cell 
epitopes recognized by high affinity TCR  (15). These pep- 
tides also induced IL-2 secretion but at concentrations fif- 
teen to ten thousand-fold higher than those inducing lytic 
activity,  (Fig.  1).  This  difference  is  unlikely  to be  due  to 
different  costimulation  requirements  for these  two  T  cell 
functions as it was observed in the context of peptide pre- 
sentation by B7 expressing APC (T2 cells  [Fig. 1] and B7-1 
transfected  melanoma  cells  [data not shown]).  Similar  dif- 
ferences between peptide concentrations required for IFN-~/ 
and lysis  triggering was also observed recently using influ- 
enza-specific CTL clones (Valitutti,  S., personal communi- 
cation). Together these data would suggest that many CTL 
clones require a higher antigen density for significant lym- 
phokine release than for cytolysis. 
TNF,  IFN-y  and  GM-CSF  secretion  were  also  mea- 
sured. Since all these responses were not simultaneously an- 
alyzed, data are expressed as a relative peptide index (as de- 
fined in Material and Methods).  Data in Table  1 confirmed 
differences in peptide concentrations required to induce ly- 
sis  and  IL-2  by  NA17-A  and  MAR.T-l-specific  T  cell 
clones. Furthermore,  peptide  concentrations needed to in- 
duce IFN-y and GM-CSF secretion by these  clones were 
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Figure  1.  Lytic  and  IL-2  responses  of  four 
MAR.T-l-specific  clones (M77) and one  NAI7- 
A-specific clone (M17.2) induced in the same stim- 
ulation experiment by the optimal melanoma pep- 
tide presented by T2 cells. 
Table 1.  Relative  Concentrations of  MART-1 and 
NA 17-A Peptides Required to Activate the Different Functions 
of Two Specific CTL Clones* 
Peptides  Cytotoxicity  IL-2  TNF  IFN~/  GM-CSF 
MART-1 
expt 1  0.15'  l  1.1 
expt 2  1 
expt 3  0.03  1  1.4 
expt 4  1  0.37 
NA17-A 
expt 1  0.005  1  0.08 
expt 2  0.005  1 
expt 3  1 
expt 4  0.15  1  0.02 
1.9 
0.53 
1.7 
0.15 
in the  same  range  than  those  required for IL-2 secretion. 
This was also the case for the induction of TNF  secretion 
by  MAP,  T-l-specific  clones  whereas  concentrations  of 
NAI7-A  peptide inducing  IL-2-were significantly higher 
than those inducing TNF secretion by the specific clone. 
Data  reported  here  estabhshed  that  melanoma  peptides 
are  true  agonists,  since  they  eflficiently stimulated  all  the 
CTL clone functions. 
Melanoma  Cells Unable to  Trigger IL-2  Secretion by  TIL 
Clones Acquire This Capacity Once Loaded with the Proper Pep- 
tide.  Although a few melanoma lines expressing NA17-A 
and  MART-1  antigens  (either  autologous  or  allogeneic) 
induced a full activation (i.e., IL-2 secretion and prolifera- 
tion) of specific TIL clones in vitro (4, 5, and unpublished 
data), many of them induced only lysis and TNF secretion 
by responding ceils. This was typically the case for the M17 
melanoma cell hne which was recognized by both MAR.T-1 
*Responses to MART-1 and NAI7-A are those from clone M77.80 
and M17.2, respectively. 
*Data are expressed as the relative peptide index (RPI) required to in- 
duce  lysis or lymphokine secretion,  compared  to the IL-2 response. 
R.P1 is calculated by dividing the concentration  of peptide inducing 
50% of maximal lysis or lymphokine production by the concentration 
of peptide inducing 50% IL-2 production.  IL-2 and TNF productions 
were determined using biological assays with the IL-2-dependent cell 
line CTLL2 and the TNF susceptible cell line WEHI 164 clone  13. 
IFN~/ and GM-CSF measurements were done with imunoenzymatic 
tests. 
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data  obtained  with  T2  cells  suggesting  requirement  for 
higher avidity TCR interactions to activate IL-2 secretion, 
we hypothesized that some melanoma cells failed to trigger  ~  100- 
full TIL activation because they did not express a sufficient  ~I~ 
density of antigenic peptides.  To address this  directly,  we  ~a 
studied the effect of incubating M17  melanoma cells with  ~  75- 
antigen-derived synthetic peptides on IL-2 secretion by tu- 
mor-specific T  cells. As shown on Figs. 2 and 3, M17 mel- 
anoma cells  pulsed with NA17-A  and MART-1  peptides  ￿9  ,i  50 - 
stimulated  both  TIL proliferation  and  IL-2  secretion  by 
TIL clones.  Therefore  preincubation  of tumor  cells  with 
adequate  concentrations  of tumor peptides rendered  these 
cells capable to fully activate specific TIL clones. Although,  ~9,  25- 
in the case of MA1kT-l-specific T  cell clones, it is difficult 
to formally prove that this result was not due to differences 
0 
between  MART-1  peptides  naturally  processed by  M17 
melanoma cells  and the synthetic peptides used here, such 
an  explanation  could  be  ruled  out  for  the  NA17-A  re- 
sponse,  since  transfection  of the  eDNA  coding  for  the 
NA17-A peptide into  M17  and other HLA-A2.1+  mela- 
noma lines led to efficient triggering of IL-2 secretion by 
TIL responders otherwise incapable  of this  response  (data 
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Figure  2.  IL-2  secretion by a MAkT-l-specifc  clone,  M7780  (.4) 
and a NAl7-A~specific clone, M17.2 (/3) induced by various concentra- 
tions  of the optimal peptide presented by M17 melanoma cells or T2 
cells. 
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Figure  3.  IL-2 secretion and proliferation of the  NA17-A-specific 
clone to M17 melanoma  cells pulsed with the appropriate  peptide. 
not  shown). Therefore, our data strongly suggest that par- 
tial activation of TIL by antigen-presenting melanoma cells 
resulted  from  low  expression  levels  of MHC-melanoma 
peptide complexes. 
All  CD8+  TIL clones  secreted  large  amounts  of IL-2 
and IFN-',/when stimulated by optimal concentrations  of 
the  antigenic  peptides.  Since  IL-2  secretion  is  not  a  fre- 
quent property of cytotoxic T  lymphocytes in other situa- 
tions, this suggests that intratumor T  cell priming by mela- 
noma antigens favors the expansion of CD8 clones with a 
good IL-2 secretion potential  and expressing high affinity 
TCR.  The  IL-2  amounts  produced  by  TIL  clones  used 
here was sufficient to induce a significant autocrine prolif- 
eration  in  vitro.  This  suggests  that  the  expression,  even 
transient,  of sufficient levels of melanoma antigens in vivo 
by either tumor cells or antigen presenting cells, could trig- 
ger the  expansion of specific IL-2-producing CTL clones 
carrying high  affinity TC1L and  activated in  an  autocrine 
fashion.  Data  presented  here  further  showed  that  despite 
lack of B7  molecules, melanoma cells  efficiently activated 
presensitized CTL clones, provided that they expressed an- 
tigens  at  high  enough  levels.  This  does  not  support  the 
widely accepted model according to which  TIL are  aner- 
gized  following  recognition  of antigen  expressing  tumor 
cells in the absence of costimulation (3). Together our data 
would rather suggest that suboptimal TIL activation by tu- 
mor cells  could result,  at  least  in part, from a too low ex- 
pression  of the  corresponding  melanoma  antigens,  by  at 
least a fraction of the tumor cells. 
The present study stresses  that lymphokine responses of 
specific T  cells  to melanoma antigens,  which likely deter- 
mines the efficiency of the antitumor response, critically de- 
pends  on MHC-peptide  density on target cells.  This sug- 
gests  that  the  efficiency  of immunization  protocols  with 
2406  Suboptimal T Cell Activation by Melanoma Antigens CTL epitopes, will tightly depend on the expression levels 
of the corresponding antigen on tumor cells. We are cur- 
rently analyzing whether the levels of MART-1 and NA17-A 
expression by melanoma lines, measured by semi-quantita- 
tive RT/PCR,  correlates with the capacity of these cells to 
induce IL-2 and IFN-~/secretion. If so, only melanoma pa- 
tients  expressing  antigens  on  their  tumor  cells  above  a 
threshold that remains to be  defined could be  eligible for 
antigen-specific immunization. 
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